GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Moat Score

IRLAB Therapeutics AB (OSTO:IRLAB A) Moat Score : 0/10 (As of Jun. 28, 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Moat Score?

IRLAB Therapeutics AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

IRLAB Therapeutics AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IRLAB Therapeutics AB might have No Moat - No discernible moat.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IRLAB Therapeutics AB Moat Score Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Moat Score
Comparable Companies
OSTO:XBRANE OSTO:IVACC OSTO:ACE OSTO:ELIC OSTO:CANTA OSTO:LIPUM OSTO:GUARD OSTO:XINT OSTO:ONCO XSAT:CESSA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
Website
https://www.irlab.se
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines